JP2020518248A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020518248A5 JP2020518248A5 JP2019560083A JP2019560083A JP2020518248A5 JP 2020518248 A5 JP2020518248 A5 JP 2020518248A5 JP 2019560083 A JP2019560083 A JP 2019560083A JP 2019560083 A JP2019560083 A JP 2019560083A JP 2020518248 A5 JP2020518248 A5 JP 2020518248A5
- Authority
- JP
- Japan
- Prior art keywords
- fragment
- antibody
- seq
- constant region
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims description 102
- 108010056102 CD100 antigen Proteins 0.000 claims description 35
- 102100027744 Semaphorin-4D Human genes 0.000 claims description 32
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 32
- 108091033319 polynucleotide Proteins 0.000 claims description 20
- 102000040430 polynucleotide Human genes 0.000 claims description 20
- 239000002157 polynucleotide Substances 0.000 claims description 20
- 239000000427 antigen Substances 0.000 claims description 13
- 102000036639 antigens Human genes 0.000 claims description 13
- 108091007433 antigens Proteins 0.000 claims description 13
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 12
- 208000027866 inflammatory disease Diseases 0.000 claims description 11
- 150000007523 nucleic acids Chemical group 0.000 claims description 11
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 10
- 208000023275 Autoimmune disease Diseases 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 239000013598 vector Substances 0.000 claims description 7
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 6
- 208000010877 cognitive disease Diseases 0.000 claims description 5
- 230000004770 neurodegeneration Effects 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 4
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 206010003591 Ataxia Diseases 0.000 claims description 3
- 201000010374 Down Syndrome Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 101100310048 Mus musculus Sema4d gene Proteins 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 208000011235 central nervous system lupus Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 claims description 2
- 208000028698 Cognitive impairment Diseases 0.000 claims description 2
- 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 claims description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 2
- 102100034384 Plexin-B1 Human genes 0.000 claims description 2
- 101710100559 Plexin-B1 Proteins 0.000 claims description 2
- 102100034383 Plexin-B2 Human genes 0.000 claims description 2
- 101710100551 Plexin-B2 Proteins 0.000 claims description 2
- 206010044688 Trisomy 21 Diseases 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000003472 neutralizing effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 230000000295 complement effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000282567 Macaca fascicularis Species 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 241001515942 marmosets Species 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023039438A JP7460819B2 (ja) | 2017-05-05 | 2023-03-14 | ヒト抗セマフォリン４ｄ抗体 |
| JP2024044422A JP2024081694A (ja) | 2017-05-05 | 2024-03-21 | ヒト抗セマフォリン４ｄ抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762501981P | 2017-05-05 | 2017-05-05 | |
| US62/501,981 | 2017-05-05 | ||
| PCT/US2018/031263 WO2018204895A1 (en) | 2017-05-05 | 2018-05-04 | Human anti-semaphorin 4d antibody |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023039438A Division JP7460819B2 (ja) | 2017-05-05 | 2023-03-14 | ヒト抗セマフォリン４ｄ抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020518248A JP2020518248A (ja) | 2020-06-25 |
| JP2020518248A5 true JP2020518248A5 (enExample) | 2021-05-13 |
| JP7246320B2 JP7246320B2 (ja) | 2023-03-27 |
Family
ID=64016767
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019560083A Active JP7246320B2 (ja) | 2017-05-05 | 2018-05-04 | ヒト抗セマフォリン４ｄ抗体 |
| JP2023039438A Active JP7460819B2 (ja) | 2017-05-05 | 2023-03-14 | ヒト抗セマフォリン４ｄ抗体 |
| JP2024044422A Pending JP2024081694A (ja) | 2017-05-05 | 2024-03-21 | ヒト抗セマフォリン４ｄ抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023039438A Active JP7460819B2 (ja) | 2017-05-05 | 2023-03-14 | ヒト抗セマフォリン４ｄ抗体 |
| JP2024044422A Pending JP2024081694A (ja) | 2017-05-05 | 2024-03-21 | ヒト抗セマフォリン４ｄ抗体 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11427634B2 (enExample) |
| EP (1) | EP3618865A4 (enExample) |
| JP (3) | JP7246320B2 (enExample) |
| KR (1) | KR102680924B1 (enExample) |
| CN (1) | CN110636858B (enExample) |
| AU (2) | AU2018261947B2 (enExample) |
| BR (1) | BR112019023138A2 (enExample) |
| CA (1) | CA3061963A1 (enExample) |
| IL (1) | IL270244B2 (enExample) |
| MX (2) | MX2019013110A (enExample) |
| NZ (1) | NZ758300A (enExample) |
| SG (1) | SG11201909466RA (enExample) |
| WO (1) | WO2018204895A1 (enExample) |
| ZA (1) | ZA201907148B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| BR112018071686A2 (pt) | 2016-04-22 | 2019-02-19 | Vaccinex, Inc. | exibição de proteínas integrais de membrana em vírions extracelulares envelopados de poxvírus |
| WO2018026715A1 (en) | 2016-08-02 | 2018-02-08 | Vaccinex, Inc. | Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells |
| CN110636858B (zh) * | 2017-05-05 | 2024-03-19 | 瓦西尼斯公司 | 人抗脑信号蛋白4d抗体 |
| US20210032322A1 (en) | 2019-08-01 | 2021-02-04 | Vaccinex, Inc. | Combined inhibition of semaphorin-4d and tgf-beta and compositions therefor |
| CN117597360A (zh) * | 2020-06-25 | 2024-02-23 | 瓦西尼斯公司 | 脑信号蛋白-4d结合分子在rett综合征治疗中的应用 |
| CA3231551A1 (en) | 2021-09-27 | 2023-03-30 | Maurice Zauderer | Predictive outcome profiling for use of an anti-semaphorin-4d binding molecule to treat neurodegenerative disorders |
| US20230331863A1 (en) | 2022-02-13 | 2023-10-19 | Vaccinex, Inc. | Combination therapy with semaphorin-4d blockade and htt-lowering agent for treatment of huntington's disease |
| KR102875105B1 (ko) * | 2023-04-03 | 2025-10-21 | 주식회사 사이알바이오 | 재조합 세마포린 4d 차단항체를 유효성분으로 포함하는 쇼그렌 증후군 예방 또는 치료용 약학 조성물 |
| CN117924494B (zh) * | 2024-01-23 | 2025-02-25 | 首都医科大学附属北京积水潭医院 | 特异性结合sema4d的抗原结合蛋白及其应用 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ201918A (en) | 1981-09-18 | 1987-04-30 | Genentech Inc | N-terminal methionyl analogues of bovine growth hormone |
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| EP0216846B2 (en) | 1985-04-01 | 1995-04-26 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| AU631802B2 (en) | 1988-06-14 | 1992-12-10 | Cetus Oncology Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| ZA902949B (en) | 1989-05-05 | 1992-02-26 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| WO1991014438A1 (en) | 1990-03-20 | 1991-10-03 | The Trustees Of Columbia University In The City Of New York | Chimeric antibodies with receptor binding ligands in place of their constant region |
| ATE218889T1 (de) | 1990-11-09 | 2002-06-15 | Stephen D Gillies | Cytokine immunokonjugate |
| FR2686087A1 (fr) | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
| AU2001297872B2 (en) | 2000-11-17 | 2006-11-09 | University Of Rochester | In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells |
| WO2002096948A2 (en) | 2001-01-29 | 2002-12-05 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| EP1442749A1 (en) | 2003-01-31 | 2004-08-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system |
| HRP20140172T1 (hr) | 2006-05-30 | 2014-03-28 | Genentech, Inc. | Protutijela i imunokonjugati kao i njihove uporabe |
| ES2396220T3 (es) | 2006-08-11 | 2013-02-20 | Ono Pharmaceutical Co., Ltd. | Anticuerpos monoclonales frente al factor 1 derivado del estroma (SDF-1) |
| EP2069404B1 (en) | 2007-02-14 | 2011-01-05 | Vaccinex, Inc. | Humanized anti-cd100 antibodies |
| FI20075278A0 (fi) | 2007-04-20 | 2007-04-20 | Biotie Therapies Corp | Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet |
| EP2157937B1 (en) | 2007-06-04 | 2017-03-22 | Sequent Medical, Inc. | Devices for treatment of vascular defects |
| MX2011002837A (es) | 2008-09-19 | 2011-07-29 | Medimmune Llc | Anticuerpos dirigidos al ligando tipo delta 4 (dll4) y usos de los mismos. |
| NO2427212T3 (enExample) | 2009-05-08 | 2018-01-20 | ||
| US9447191B2 (en) | 2011-05-13 | 2016-09-20 | National University Corporation Tokyo Medical And Dental University | Osteogenesis promoter |
| CN104168956A (zh) * | 2011-10-11 | 2014-11-26 | 瓦西尼斯公司 | 臂板蛋白-4d结合分子用于调节血脑屏障渗透性的用途 |
| US9090709B2 (en) * | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| BR112015032690B1 (pt) | 2013-06-25 | 2020-03-10 | Vaccinex, Inc. | Uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir o crescimento tumoral e metástase |
| NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) * | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| CN104127862A (zh) * | 2014-08-14 | 2014-11-05 | 武汉大学 | Semaphorin 4D在预防及治疗骨代谢性疾病中的应用 |
| AU2015367684A1 (en) * | 2014-12-15 | 2017-07-06 | Galapagos Nv | Antibodies for IL-17C |
| CN110636858B (zh) * | 2017-05-05 | 2024-03-19 | 瓦西尼斯公司 | 人抗脑信号蛋白4d抗体 |
| CN117597360A (zh) * | 2020-06-25 | 2024-02-23 | 瓦西尼斯公司 | 脑信号蛋白-4d结合分子在rett综合征治疗中的应用 |
-
2018
- 2018-05-04 CN CN201880029632.7A patent/CN110636858B/zh active Active
- 2018-05-04 CA CA3061963A patent/CA3061963A1/en active Pending
- 2018-05-04 IL IL270244A patent/IL270244B2/en unknown
- 2018-05-04 MX MX2019013110A patent/MX2019013110A/es unknown
- 2018-05-04 NZ NZ758300A patent/NZ758300A/en unknown
- 2018-05-04 AU AU2018261947A patent/AU2018261947B2/en active Active
- 2018-05-04 SG SG11201909466R patent/SG11201909466RA/en unknown
- 2018-05-04 WO PCT/US2018/031263 patent/WO2018204895A1/en not_active Ceased
- 2018-05-04 US US16/611,209 patent/US11427634B2/en active Active
- 2018-05-04 BR BR112019023138-2A patent/BR112019023138A2/pt unknown
- 2018-05-04 JP JP2019560083A patent/JP7246320B2/ja active Active
- 2018-05-04 KR KR1020197034009A patent/KR102680924B1/ko active Active
- 2018-05-04 EP EP18793831.1A patent/EP3618865A4/en active Pending
-
2019
- 2019-10-29 ZA ZA2019/07148A patent/ZA201907148B/en unknown
- 2019-11-04 MX MX2023003519A patent/MX2023003519A/es unknown
-
2022
- 2022-07-19 US US17/813,375 patent/US12006365B2/en active Active
-
2023
- 2023-03-14 JP JP2023039438A patent/JP7460819B2/ja active Active
-
2024
- 2024-03-21 JP JP2024044422A patent/JP2024081694A/ja active Pending
- 2024-05-03 US US18/654,538 patent/US20240309091A1/en active Pending
- 2024-07-10 AU AU2024204752A patent/AU2024204752A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020518248A5 (enExample) | ||
| CN102439040B (zh) | 抗TNF‑α抗体和其用途 | |
| CN112135626A (zh) | 抗tigit抗体及其用途 | |
| JP2011509245A5 (enExample) | ||
| RU2009128064A (ru) | Антитела к cd44 | |
| WO2019034580A1 (en) | HUMANIZED ANTIBODIES FOR CD3 | |
| JP2020534830A5 (enExample) | ||
| AU2016223095A1 (en) | Antibodies to tau and uses thereof | |
| AU2014248636B2 (en) | Humanized anti-N2 antibodies | |
| AU2011282476A1 (en) | Anti-IL-23 heterodimer specific antibodies | |
| RU2020130795A (ru) | Нейтрализующие антитела к env вич-1 и их применение | |
| JP2005528914A5 (enExample) | ||
| WO2015191934A2 (en) | Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases | |
| JP2020515277A5 (enExample) | ||
| JP2019516392A5 (enExample) | ||
| FI4200018T3 (fi) | Anti-par-2-vasta-aineet ja niiden käyttömenetelmät | |
| JP2025170398A (ja) | 試料中のポリペプチドの検出または捕捉において使用するための抗体、および組成物、ならびに試料中のポリペプチドの検出または捕捉のための方法 | |
| JPWO2019186276A5 (enExample) | ||
| CN109721656B (zh) | 靶向rankl的治疗性抗体 | |
| JPWO2020011973A5 (enExample) | ||
| JP2019509714A5 (enExample) | ||
| JP2019518473A5 (enExample) | ||
| CN115151567A (zh) | 治疗性Fc组合物的化学诱导结合和解离以及T细胞接合器与人血清白蛋白的化学诱导二聚化 | |
| JP7641292B2 (ja) | 抗ｃｄ１９抗体、その使用方法及び製造方法 | |
| RU2019131732A (ru) | Антитела человека против семафорина 4d |